Prelude Capital Management, LLC Glycomimetics Inc Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $56,145 - $257,668	-20,052 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.6 - $13.12 $25,948 - $32,117	2,448 Added 13.91%	20,052 $239,000
Q1 2019 May 15, 2019	BUY	$9.96 - $13.44 $173,234 - $233,761	17,393 Added 8243.13%	17,604 $219,000
Q4 2018 Feb 14, 2019	SELL	$8.47 - $14.71 $2,795 - $4,854	-330 Reduced 61.0%	211 $2,000
Q3 2018 Nov 14, 2018	BUY	$13.7 - $17.12 $3,027 - $3,783	221 Added 69.06%	541 $8,000
Q2 2018 Aug 14, 2018	BUY	$14.63 - $19.19 $4,681 - $6,140	320 New	320 $5,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.